SKIN - NASDAQ
The Beauty Health Company
$0.63
-9.8%The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
At a Glance
Live SnapshotThe Beauty Health Company Management Team
Mr. Michael P. Monahan
Chief Financial Officer
Compensation
$605,524
Ms. Celeste Ortiz
Chief Human Resources Officer
Ms. Carrie Caulkins
Chief Marketing Officer
Mr. Ronald Menezes
Chief Revenue Officer & Executive Officer
Ms. Sheri Lewis
Chief Supply Chain & Operations Officer
Ms. Marla Malcolm Beck
President, Chief Executive Officer & Director
Compensation
$1,982,469
Mr. Paul Bokota J.D.
Senior Vice President & General Counsel
The Beauty Health Company Insider Positioning
During the last 12 months, insiders have purchased $1.92M and sold $128K worth of SKIN shares, resulting in $1.79M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
1.2M
1.92M
46.4K
66.39K
+1.9M
+$1.85M
9-12 Months
0
0.00
32.4K
61.15K
-61K
-$61K
Top Buyers
Malha Pedro Bruno Ferreira
Director, Officer: President And Ceo
$1.92M
Top Sellers
Menezes Ronald
Officer: Chief Revenue Officer
$66K
Monahan Michael P.
Officer: Chief Financial Officer
$61K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $1.79M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
2 insider sellers vs. 1 buyers. More insiders selling than buying suggests cautious or negative sentiment.
SEC Filings
SKIN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
DEF 14A DEF 14A 2022 N/A | May 12, 2022 | June 28, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.